Y. Ye et al. / Bioorg. Med. Chem. 17 (2009) 5722–5732
5731
(4.6 mm ꢁ 150 mm I.D; Agilent Technologies, Chadds Ford, PA,
USA) maintained at 25 °C. The LC mobile phase was CH3CN/H2O/
HCOOH (80:20:0.5, v/v) at a flow rate of 0.5 mL/min for an isocratic
elution. The mass spectrometer was operated in the positive ion
electrospray ionization and multiple-reaction monitoring modes
for 11e. The instrument parameters were optimized for the analyte
to maximize generation of the protonated molecules and to effi-
ciently produce the characteristic fragment ions. The precursor-
to-product ion transitions m/z 540?418 for 11e were monitored
with a scan time of 0.3 s per transition. The pharmacokinetic
parameters are summarized in Table 3.
08QH14028) and the Dengsan Project from the Shanghai Science
and Technology Commission (Grant 064319015).
References and notes
1. Kargul, J.; Laurent, G. J. Int. J. Biochem. Cell Biol. 2006, 38, 685.
2. Olefsky, J. M.; Ciaraldi, T. P.; Kolterman, O. G. Am. J. Med. 1985, 79, 12.
3. (a) Willson, T. M.; Lambert, M. H.; Kliewer, S. A. Annu. Rev. Biochem. 2001, 70,
341; (b) Alberts, P.; Engblom, L.; Edling, N.; Forsgren, M.; Klingstrom, G.;
Larsson, C.; Ronquist-Nii, Y.; Ohman, B.; Abrahmsen, L. Diabetologia 2002, 45,
1528.
4. Berger, J.; Moller, D. E. Annu. Rev. Med. 2002, 53, 409.
5. Vidal-Puig, A. J.; Considine, R. V.; Jimenez-Linan, M.; Werman, A.; Pories, W. J.;
Caro, J. F.; Flier, J. S. J. Clin. Invest. 1997, 99, 2416.
6. (a) Freedman, L. P. Cell 1999, 97, 5; (b) Miyata, K. S.; McCaw, S. E.; Marcus, S. L.;
Rachubinski, R. A.; Capone, J. P. Gene 1994, 148, 327; (c) Kliewer, S. A.;
Umesono, K.; Noonan, D. J.; Heyman, R. A.; Evans, R. M. Nature 1992, 358, 771.
7. (a) Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W. O.; Willson, T.
M.; Kliewer, S. A. J. Biol. Chem. 1995, 270, 12953; (b) Momose, Y.; Meguro, K.;
Ikeda, H.; Hatanaka, C.; Oi, S.; Sohda, T. Chem. Pharm. Bull. (Tokyo) 1991, 39,
1440; (c) Cantello, B. C.; Cawthorne, M. A.; Cottam, G. P.; Duff, P. T.; Haigh, D.;
Hindley, R. M.; Lister, C. A.; Smith, S. A.; Thurlby, P. L. J. Med. Chem. 1994, 37,
3977.
8. (a) Scheen, A. J. Drug Saf. 2001, 24, 873; (b) Nissen, S. E.; Wolski, K. N. Engl. J.
Med. 2007, 356, 2457.
9. (a) Seckl, J. R.; Walker, B. R. Endocrinology 2001, 142, 1371; (b) Kotelevtsev, Y.;
Holmes, M. C.; Burchell, A.; Houston, P. M.; Schmoll, D.; Jamieson, P.; Best, R.;
Brown, R.; Edwards, C. R.; Seckl, J. R.; Mullins, J. J. Proc. Natl. Acad. Sci. U.S.A.
1997, 94, 14924.
6.3.5. In vivo KKAy mice studies
KKAy mice were purchased from Shanghai SLAC Laboratory Ani-
mal CO. LTD (Shanghai, China) and maintained under a 12:12 light/
dark cycle with free access to water and food. The mice were ran-
domized to different treatment groups according to the experi-
ment designation by body weight and fed glucose levels (n = 10).
Compound 11e in 0.25% CMC-Na (20 mg/kg), rosiglitazone in
0.25% CMC-Na (10 mg/kg) or vehicle were administrated orally
for 6 weeks. Blood glucose levels were measured twice a week.
At the end of the experiment, mice were fasted for 4 h before sac-
rifice and then blood samples were obtained to measure glucose,
TG, and other serum biochemical indicators. All these procedures
were approved by the Local Ethical Board.
10. (a) Kershaw, E. E.; Morton, N. M.; Dhillon, H.; Ramage, L.; Seckl, J. R.; Flier, J. S.
Diabetes 2005, 54, 1023; (b) Morton, N. M.; Paterson, J. M.; Masuzaki, H.;
Holmes, M. C.; Staels, B.; Fievet, C.; Walker, B. R.; Flier, J. S.; Mullins, J. J.; Seckl, J.
R. Diabetes 2004, 53, 931.
11. Boyle, C. D. Curr. Opin. Drug Discovery Dev. 2008, 11, 495.
12. Wang, M. Curr. Opin. Invest. Drugs 2006, 7, 319.
13. Kim, J.; Temple, K. A.; Jones, S. A.; Meredith, K. N.; Basko, J. L.; Brady, M. J. J. Biol.
Chem. 2007, 282, 11038.
14. Liu, Y.; Park, F.; Pietrusz, J. L.; Jia, G.; Singh, R. J.; Netzel, B. C.; Liang, M. Physiol.
Genomics 2008, 32, 343.
15. (a) Bujalska, I. J.; Kumar, S.; Hewison, M.; Stewart, P. M. Endocrinology 1999,
140, 3188; (b) Bujalska, I. J.; Gathercole, L. L.; Tomlinson, J. W.; Darimont, C.;
Ermolieff, J.; Fanjul, A. N.; Rejto, P. A.; Stewart, P. M. J. Endocrinol. 2008, 197,
297.
16. Xu, Y.; Rito, C. J.; Etgen, G. J.; Ardecky, R. J.; Bean, J. S.; Bensch, W. R.; Bosley, J.
R.; Broderick, C. L.; Brooks, D. A.; Dominianni, S. J.; Hahn, P. J.; Liu, S.; Mais, D.
E.; Montrose-Rafizadeh, C.; Ogilvie, K. M.; Oldham, B. A.; Peters, M.; Rungta, D.
K.; Shuker, A. J.; Stephenson, G. A.; Tripp, A. E.; Wilson, S. B.; Winneroski, L. L.;
Zink, R.; Kauffman, R. F.; McCarthy, J. R. J. Med. Chem. 2004, 47, 2422.
17. Li, Z.; Liao, C.; Ko, B. C.; Shan, S.; Tong, E. H.; Yin, Z.; Pan, D.; Wong, V. K.; Shi, L.;
Ning, Z. Q.; Hu, W.; Zhou, J.; Chung, S. S.; Lu, X. P. Bioorg. Med. Chem. Lett. 2004,
14, 3507.
18. Mundt, S.; Solly, K.; Thieringer, R.; Hermanowski-Vosatka, A. Assay Drug Dev.
Technol. 2005, 3, 367.
19. Sampath-Kumar, R.; Yu, M.; Khalil, M. W.; Yang, K. J. Steroid Biochem. Mol. Biol.
1997, 62, 195.
20. Sorensen, B.; Winn, M.; Rohde, J.; Shuai, Q.; Wang, J.; Fung, S.; Monzon, K.;
Chiou, W.; Stolarik, D.; Imade, H.; Pan, L.; Deng, X.; Chovan, L.; Longenecker, K.;
Judge, R.; Qin, W.; Brune, M.; Camp, H.; Frevert, E. U.; Jacobson, P.; Link, J. T.
Bioorg. Med. Chem. Lett. 2007, 17, 527.
21. Jean, D. J., Jr.; Yuan, C.; Bercot, E. A.; Cupples, R.; Chen, M.; Fretland, J.; Hale, C.;
Hungate, R. W.; Komorowski, R.; Veniant, M.; Wang, M.; Zhang, X.; Fotsch, C. J.
Med. Chem. 2007, 50, 429.
22. Sun, D.; Wang, Z.; Di, Y.; Jaen, J. C.; Labelle, M.; Ma, J.; Miao, S.; Sudom, A.; Tang,
L.; Tomooka, C. S.; Tu, H.; Ursu, S.; Walker, N.; Yan, X.; Ye, Q.; Powers, J. P.
Bioorg. Med. Chem. Lett. 2008, 18, 3513.
6.3.6. In vivo MSG rats studies
The neonatal administration of monosodium L-glutamate (MSG)
in rodents damages the arcuate nuclei of the hypothalamus, thus
resulting in a syndrome characterized by stunted growth, hyperad-
iposity, and hypogonadism during adulthood. Therefore, MSG rats
is a well established model of obesity. New born Wister rats were
bought from Shanghai SLAC Laboratory Animal CO. LTD (Shanghai,
China) and subcutaneous injected with 4 g/kg MSG since the sec-
ond day of birth for 7 days, weaning on the 21 day. At the age of
11–12 months, MSG rats were randomized to three groups by body
weight and serum TG levels. Rats were orally dosed with 10 mg/
kg d compound 11e or 5 mg/kg d rosiglitazone or vehicle for
6 weeks. During dosing, body weight, blood glucose levels and ser-
um TG levels were measured once a week after 10 h fast. After sac-
rificed, the weight of organs, body fat, viseral and subcutaneous fat
were measured blood samples were obtained to measure glucose,
TG, and other serum biochemical indicators.
6.4. Molecular modeling of a typical compound with PPAR
and 11b-HSD1
c
The crystal structure of PPARc and 11b-HSD1 in complexes with
GI262570 (1FM9),33 and CBO, respectively, recovered from the
Brookhaven Protein Data Bank was used as the target for molecular
23. Patani, G. A.; LaVoie, E. J. Chem. Rev. 1996, 96, 3147.
docking. The docking calculations of compound 11e with PPAR
c
were performed with AUTODOCK 3.0 program.34 Up to 10 different
docking solutions were obtained for each molecule. All docking
conformations in the different receptor conformers were then
ranked with AUTODOCK 3.0 scoring function. For each compound, a
combination of the free energy score and visual inspection of the
binding mode were applied to choose the best conformation for
further analysis.
24. Nolte, R. T.; Wisely, G. B.; Westin, S.; Cobb, J. E.; Lambert, M. H.; Kurokawa, R.;
Rosenfeld, M. G.; Willson, T. M.; Glass, C. K.; Milburn, M. V. Nature 1998, 395.
25. Kletzien, R. F.; Clarke, S. D.; Ulrich, R. G. Mol. Pharmacol. 1992, 41, 393.
26. (a) Fuchtenbusch, M.; Standl, E.; Schatz, H. Exp. Clin. Endocrinol. Diabetes 2000,
108, 151; (b) Bogacka, I.; Xie, H.; Bray, G. A.; Smith, S. R. Diabetes Care 2004, 27,
1660.
27. Morton, N. M.; Holmes, M. C.; Fievet, C.; Staels, B.; Tailleux, A.; Mullins, J. J.;
Seckl, J. R. J. Biol. Chem. 2001, 276, 41293.
28. (a) Berger, J.; Tanen, M.; Elbrecht, A.; Hermanowski-Vosatka, A.; Moller, D. E.;
Wright, S. D.; Thieringer, R. J. Biol. Chem. 2001, 276, 12629–12635; (b) Wake, D.
J.; Stimson, R. H.; Tan, G. D.; Homer, N. Z.; Andrew, R.; Karpe, F.; Walker, B. R. J.
Clin. Endocrinol. Metab. 2007, 92, 1848.
29. (a) W. Wallace, H.; Christy, S.B.; Joan, G.W.; Naphtali, O.M.; Jane, G.B; David,
C.L; William, R.O; Michael, C.L; Diane, M.I. PPAR Res. 2007, 2007, 97125.; (b)
King, A. B. Diabetes Care 2000, 23, 557.
30. (a) Carmona, M. C.; Louche, K.; Lefebvre, B.; Pilon, A.; Hennuyer, N.; Audinot-
Bouchez, V.; Fievet, C.; Torpier, G.; Formstecher, P.; Renard, P.; Lefebvre, P.;
Dacquet, C.; Staels, B.; Casteilla, L.; Penicaud, L. Diabetes 2007, 56, 2797; (b)
Misra, P.; Chakrabarti, R.; Vikramadithyan, R. K.; Bolusu, G.; Juluri, S.; Hiriyan,
Acknowledgments
We gratefully acknowledge financial support from the National
Natural Science Foundation of China (Grants 30623008), the Na-
tional Basic Research Program of China (973 Program,
2009CB522300), Shanghai Rising-Star Foundation (Grant